India's largest bank SBI to invest $20 mn in fintech firm Pine Labs
Pine Labs, a leading merchant commerce platform, announced a new investment of $20 million from India’s largest commercial bank, the State Bank of India (SBI).
Earlier in 2021, Pine Labs had raised a total round size of $600 million from a marquee set of new investors and followed it up with a $100 million fundraise from US-based Invesco Developing Markets Fund. Read more
Dr Reddy's to launch Molflu at Rs 35 per capsule for Covid treatment
Indian drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir, and price it at Rs 35 ($0.4693) per capsule, a company spokesperson said on Tuesday.
The overall cost for a patient treated with a 5-day course of 40 capsules of the generic drug, to be sold under brand name 'Molflu', will come up to Rs 1,400 ($18.77). In comparison, the treatment with Merck's pill in the United States costs $700. Read more
Delhi HC rejects Future's plea for termination of Amazon arbitration
The Delhi High Court on Tuesday dismissed the pleas moved by Future Group companies seeking a direction to the arbitration tribunal, which is adjudicating on Amazon's objections against their deal with Reliance, to take a decision on their application for the termination of the arbitration proceedings before moving any further.
"Both the petitions are dismissed," said Justice Amit Bansal, who had reserved the order on the petitions filed by Future Coupons Private Limited (FCPL) and Future Retail Limited (FRL) on January 3. Read more
Delhi logs 5,481 new Covid cases, most since May 16; positivity rate 8.37%
Delhi reported 5,481 fresh COVID-19 cases on Tuesday, the highest number of such cases since May 16, with a positivity rate of 8.37 per cent, and three more fatalities due to the viral disease, according to data shared by the city health department.
The national capital had recorded 6,456 fresh COVID-19 cases and 262 fatalities on May 16, while the case positivity rate stood at 10.4 per cent. Read more
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU